Background and Significance
Despite advances in medicine and decades of evidence, there has been little improvement in intracerebral hemorrhage (ICH) morbidity and mortality. The AHA recently released a statement, “Code ICH: A Call to Action”. Code ICH aims to establish a protocol, like acute ischemic stroke management, to bundle care, and improve outcomes in patients with ICH. Within the consensus statement, blood pressure management and anticoagulation reversal within 60 minutes of arrival are recommended. Additionally, the AHA has quality metrics for anticoagulation-associated ICH patients with a goal of receiving reversal within 90 minutes of arrival. Despite “Code ICH” publication in early 2024, there have been limited studies evaluating the achievement of these measurements or assessment of factors associated with treatment delays. Therefore, the goal of this investigation is to describe the proportion of patients presenting with ICH who receive Code-ICH Bundle-concordant care and its impact on outcomes.
Objectives/Aims
- To determine the proportion of patients with spontaneous ICH who receive Code-ICH Bundle-concordant treatments for hypertension
- Describe the rate of antihypertensive agent initiation within 60 minutes of emergency department arrival (Code-ICH measurement) in patients with spontaneous ICH with initial SBP > 150 mmHg.
- Describe the rate of achieving goal blood pressure within 1 hour of arrival in patients with spontaneous ICH presenting SBP > 150 mmHg.
- Describe the rate of achieving sustained goal blood pressure management within 3 hours of arrival in patients with spontaneous ICH presenting SBP > 150 mmHg.
- To determine the proportion of patients with spontaneous ICH who receive Code-ICH Bundle-concordant anticoagulant reversal.
- Describe the rate of receiving anticoagulation reversal within 60 minutes of arrival (Code-ICH measurement) in patients with anticoagulation-associated spontaneous ICH.
- Describe the rate of receiving anticoagulation reversal within 90 minutes of arrival (AHA measurement) in anticoagulation-associated spontaneous ICH patients.
- Identify factors associated with delays in antihypertensive and anticoagulation reversal initiation in patients with spontaneous ICH.